Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1992-06-24
1995-07-18
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514170, 514177, 514179, 523113, 424422, A61K 3156
Patent
active
054341469
ABSTRACT:
Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolaR serum concentration) administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell
patent: 4107071 (1978-08-01), Bayless
patent: 4166800 (1979-09-01), Fong
patent: 4659695 (1987-04-01), Labrie
patent: 4818542 (1989-04-01), DeLuca
patent: 4826831 (1989-05-01), Plunkett et al.
patent: 4987268 (1991-01-01), Rauleder
patent: 5043331 (1992-08-01), Hirvonen et al.
The Merck Index, 1989, Citation No. 7486, Pizotyline, p. 1194.
Chemical Abstracts, vol. 97, No. 4, 26 Jul. 1982, Columbus Ohio, Abstract No. 28542e.
The Merck Index, 1989, Merck & Co. Inc., Rahway, N.J., p. 909, No. 5677; p. 910 No. 5687.
Adair, F. E. (1947) The use of the male sex hormone in women with breast cancer, Surg. Gynecol. Obstet. 84:719-722.
Adair, F. E., Herrmann, J. B. (1946) The use of testosterone propionate in the treatment of advanced carcinoma of the breast. Ann. Surg 123:1023-1035.
Adair, F. E., Mellors, R. C., Farrow, J. H., Woodard, H. Q., Escher, C. S., Urban, J. A. (1949) The use of estrogens and androgens in advanced mammary cancer. J. Am. Med. Ass. 15:1193-1200.
Allegra, J. C., Lippman, M. E., Thompson, E. B., Simon, R., Barlock, A., Green, L., Huff, K. K., Do, H. M. T., Aitken, S. C. (1979) Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 39:1447-1454.
Aloia, J. F., Vaswanim, A. N., Yed, J. K., Ross, P., Ellis, K., Cohn, S. H. (1983) Determinants of bone mass in postmenopausal women. Arch. Int. Med. 143:1700-1704.
Anderson, L. C., Wise, D. L., Howes, J. F. (1976) An injectable sustained release fertility control system. Contraception 13:375-384.
Baker, R. (1987) Controlled release of biologically active agents. John Wiley & Sons, Inc.
Beck, L. R., Tice, T. R. (1983) Poly(lactic acid) and poly(lactic acid-co-glycolic acid) contraceptive delivery systems. In: Advances in Human Fertility and Reproductive Endocrinology. Edited by D. R. Mishell Jr., vol. 2, Raven Press, New York, pp. 175-199.
Blossey, H. C., Wander, H. E., Kiebberling, J., Nagel, G. A. (1984) Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate. Cancer 54:1207-1215.
Blumenschein, G. R. (1983) The role of progestins in the treatment of breast cancer. Semin. Oncol. 10:7-10.
Centola, G. M. (1985) Inhibition of endometrial carcinoma cell cultures by a synthetic androgen. Cancer Res. 45:6264-6267.
Colvard, D. S., Eriksen, E. F., Keeting, P. E., Wilson, E. M., Lubahn D. B., French, F. S., Riggs, B. L., Spelsberg, T. C. (1989) Identification of androgen receptors in normal human osteoblast-like cells. Proc. Natl. Acad. Sci. 86:854-857.
Deutsch, S., Benjamin, F., Seltzer, V., Tafreshi, M., Kocheril, G., Frank, A. (1987) The correlation of serum estrogens and androgens with bone density in the late postmenopause. Int. J. Gynecol. Obstet. 25:217-222.
Ehrlich, C. E., Young, P. C. M., Stehman, F. B., Sutton, G. P., Alfort, W. M. (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am. J. Obstet. Gynecol. 158:797-807.
Eriksen, E. F., Colvard, D. S., Berg, N. J., Graham, M. L., Mann, K. G., Spelsbert, C., Riggs, B. L. (1988) Evidence of estrogen receptors in normal human osterblast-like cells. Science 241:84-86.
Finkelstein, J. S., Linbanski, A., Neer, R. M., Greenspan, S. L., Rosenthal, D. I., Crowley, W. F. Jr (1987) Osteoporosis in men with idiopathic hypogonadotropic hypogonadism. Ann. Intern. Med. 106:354-361.
Gresser, J. D., Wise, D. L., Beck, L. R., Howes, J. F. (1978) Larger animal testing of an injectable sustained release fertility control system. Contraception 17:253-267.
Hall PE (1987) Long acting injectable preparations. Edited by E. Diczfalusy, M. Bydeman M. In:Fertility Regulation, Today and Tomorrow. New York, Raven Press, pp. 119-141.
Haller, F. G., Glick, J. H. (1986) Progestational agents in advanced breast cancer: an overview. Semin. Oncol. 13:2-8.
Hamblen EC (1957) Androgenic therapy for woman. South Med J 50: 743-750.
Hollo, I., Feher, T., Szucs, J. (1970) Serum dehydroepiandrosterone, androsterone and cortisol level in primary postmenopausal and other type osteoporosis. Acta Med. Hung. 27:155-160.
Hollo, I. Feher, T. (1964) Studies on postmenopausal osteoporosis. I. Urinary excretion of 17-ketosteroid fractions in postmenopausal osteoporosis. Acta Med. Hung. 20:233-247.
Hollo, I., Szalay, F., Szucs, J., Boross, M. (1976) Osteoporosis and androgens. Lancet 1357.
Hortobagyi, G. N., Buzdar, A. M., Frye, D., Yap, H. Y., Hug, V., Pinnamaneni, K., Fraschini, G., Halvorson, H. C., Blumenschein, G. R. (1985) Oral medroxyprogesterone acetate in the treatent of metastatic breast cancer. Breast Cancer Res. Treatm. 5:321-326.
Horwitz, K. B. (1987) The structure and function of progesterone receptors in breast cancer. J. Steroid Biochem. 27:447-457.
Horwitz, K. B., Zava, D. T., Thilagar, A. K., Jensen, E. M., McGuire, W. L. (1978) Sterod receptor analyses of nine human breast cancer cell lines. Cancer Res. 38:2434-2439.
Janne, O. A., Bardin, C. W. (1984) Steroid receptors and hormone action: physiological and synthetic androgens and progestins can mediate inappropriate biological effects. Pharmacol. Rev. 36:35S-42S.
Kitchell, J. D. and Wise, D. L. (1985). [32]poly(lactic/glycolic acid) biodegradable drug-polymer matrix system. In Methods in Enzumology, Academic Press, vol. 112, pp. 436-448.
Komm, B. S., Terpening, C. M., Benz, D. J., Graeme, K. A., Gallegos, A., Korc, M., Greene, G. L., O'Malley, B. W., Haussler, M. R. (1988) Estrogen binding, receptor mRNA, and biologic response in osteoblast-like ostersarcoma cells. Science 241:81-84.
Kramer, C. Y. (1956) Extension of multiple range tests to group means with unequal numbers of replications. Biometrics 12:307-310.
Labrie, C., Cusan, L., Plante, M., Lapointe, S., Labrie, F. (1987) Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem. 28:379-384.
Labrie, C., Simard, J., Zhao, H. F., Pelletier, G., Labrie, F. (1990) Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate. Mol. Cell. Endocrinol. 68:169-179.
Labrie, F., Ferland, L., Lagace, L., Drouin, J., Asselin, J., Azadian-Boulanger, G., Raynaud, J. P. (1977) High inhibitory activity of R5020, a pure progestin, at the hypothalamic-adenohypophyseal level on gonadotropin secretion. Fertil. Steril. 28: 1104-1112.
Larrea, F., Vilchis, F., Chavez B., Perez, A. E., Garza-Flores, J., Perez-Palacios, G. (1987) The metabolism of 19-nor contraceptive progestins modulates their biological activity at the neuroendocrine level. J. Steoid Biochem. 27:657-663.
Lea, O. A., Kvinnsland, S., Thorsen, T. (1989) Improved measurement of androgen receptors in human breast cancer. Cancer Res. 49:7162-7167.
Lim F. (1984) Biomedical Application of microencapsulation. Edited by F. Lim. CRC Press, BocaRaton.
Lippman, M. E. (1983) Antiestrogen therapy of breast cancer. Semin. Oncol. 10:11-19.
Lippman, M., Bolan, G., Huff, K. (1976) The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue cultur. Cancer Res. 36:4610-4618.
MacLaughlin, D. T., Richardson, G. S. (1979) Specificity of medroxyprogesterone acetate binding in human endometrium: interaction with testosterone and progesterone binding sites. J. Steroid Biochem. 10:371-377.
Mattson, W. (1983) Current status of high dose progestin treatment in advanced breast cancer. Breast Cancer Res. Treatm. 3:231-235.
Muechler, E. K., Kohler, D. (1988) Dihydrotestosterone-binding by human endometrium. Society for Gynecol. Invest. 8
Labrie Fernand
Lepage Martin
Endorecherche Inc.
Nutter Nathan M.
LandOfFree
Controlled release systems and low dose androgens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release systems and low dose androgens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release systems and low dose androgens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2419056